Medivir to present at the Pareto Securities Healthcare Conference
Rhea-AI Summary
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company specializing in innovative cancer treatments, has announced its participation in the Pareto Securities Healthcare Conference on September 19, 2024. CEO Jens Lindberg will present an update on the mature and detailed data from the phase 1b/2a study of fostrox-+ Lenvima® in advanced hepatocellular carcinoma (HCC), which was recently showcased at the ESMO conference.
The presentation will be made available on Medivir's website following the event. This announcement highlights Medivir's commitment to sharing important research findings and engaging with the healthcare investment community.
Positive
- None.
Negative
- None.
CEO Jens Lindberg will provide an update on the mature and detailed data from the phase 1b/2a study with fostrox-+ Lenvima® in advanced hepatocellular carcinoma (HCC) recently presented at the ESMO conference.
The presentation will be available on Medivir's website after the meeting.
For more information about the event, please visit www.paretosec.com
For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-pareto-securities-healthcare-conference-302251788.html
SOURCE Medivir
FAQ
When is Medivir (MVIR) presenting at the Pareto Securities Healthcare Conference?
What will Medivir's CEO discuss at the Pareto Securities Healthcare Conference?
Where was the fostrox-+ Lenvima® study data for HCC recently presented by Medivir (MVIR)?
Will Medivir's (MVIR) Pareto Securities Healthcare Conference presentation be available online?
